Uganda receives 1,200 doses of experimental Ebola vaccine
By Arsenio Toledo // Dec 09, 2022

The East African nation of Uganda has received a shipment of 1,200 Ebola vaccine candidates to be used in human trials in the country.

The World Health Organization (WHO) previously pledged to provide Uganda with three vaccine candidates to be used in human trials – one created jointly by the University of Oxford in the United Kingdom and the Serum Institute of India, another by the Washington, D.C. non-profit the Sabin Vaccine Institute and a third by New Jersey-based Big Pharma Merck & Co. (Related: Uganda reports 14 new cases of UNTREATABLE Ebola strain infection.)

Ugandan Minister of Health Jane Ruth Aceng received the first batch of vaccine doses in a ceremony featuring representatives from both the Ugandan government and the WHO on Thursday, Dec. 8, in the small city of Entebbe, about 28 miles south of the capital Kampala.

"Today, we are happy that we have the first batch," she said, talking about the 1,200 doses from the Sabin Vaccine Institute. "We shall be receiving other doses from Merck and from Oxford."

The vaccines will be used in a "ring vaccination trial." This means that close contacts of confirmed Ebola patients and the contacts of close contacts will be vaccinated along with the country's healthcare and other frontline workers.

WHO Regional Director for Africa Dr. Marshidiso Moeti hailed the vaccine trial as "a promising step towards possible protection against the virus."

Ebola outbreak in Uganda waning, vaccines unnecessary

The Ebola outbreak in Uganda began on Sept. 20 and has infected around 142 people in the country of nearly 46 million. Of these, 86 people recovered from the Ebola virus's symptoms, including hemorrhagic fever, vomiting, diarrhea, muscle pain and internal and external bleeding.

Furthermore, the Ugandan government has noted that the country has not had an active Ebola case in nine days, with the last Ebola patient being discharged from the hospital on Dec. 2 after dealing with a bout of hemorrhagic fever.

According to WHO criteria, an outbreak of the Ebola virus ends when there are no new cases for 42 consecutive days, which is twice the incubation period of Ebola.

"We are nine days today on the countdown," said Aceng. "So, it does not mean we will not get another [Ebola] case. Uganda is a country that always wants to be prepared and ready whenever any outbreak occurs."

If no new infections are registered, the Ugandan government expects to declare the country free of the virus by Jan. 10. But regardless of whether or not there are new Ebola cases, the vaccine trial will continue.

"Even if there are no cases, and no contacts and no suspects, the Ministry of Health will still request the scientists to continue with the study," she added. "Uganda so far has had seven Ebola outbreaks. We may yet again get another Ebola outbreak."

Both the WHO and the Ugandan government are interested in the vaccine trial because there are currently no licensed vaccines for the Sudan strain of the Ebola virus that caused the country's latest outbreak. The trial is being used to determine whether any or all of the three vaccine candidates are effective in combating the Sudan strain.

Vaccines already exist for the more common Zaire strain of the Ebola virus, which spread during recent outbreaks in the neighboring Democratic Republic of the Congo.

Learn more about disease outbreaks at

Watch this clip from InfoWars featuring Harrison Smith discussing how the Ebola outbreak in Uganda made globalists "rub hands and drool" at the opportunity to exert more control over the world.

This video is from the InfoWars channel on

More related stories:

Uganda declares three-week lockdown in two districts amid new Ebola outbreak.

Endless fear merry-go-round: WHO says Ebola risk is now "very high."

CDC and FDA "tag-teaming" Ebola bioweapons psy-op to push dangerous vaccines as part of an Ebola outbreak mass theater operation.

Huh? Ebola vaccine not being tested against Ebola.

Sources include:

Take Action:
Support NewsTarget by linking to this article from your website.
Permalink to this article:
Embed article link:
Reprinting this article:
Non-commercial use is permitted with credit to (including a clickable link).
Please contact us for more information.
Free Email Alerts
Get independent news alerts on natural cures, food lab tests, cannabis medicine, science, robotics, drones, privacy and more. © 2022 All Rights Reserved. All content posted on this site is commentary or opinion and is protected under Free Speech. is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published on this site. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

This site uses cookies
News Target uses cookies to improve your experience on our site. By using this site, you agree to our privacy policy.
Learn More
Get 100% real, uncensored news delivered straight to your inbox
You can unsubscribe at any time. Your email privacy is completely protected.